InSilico Medicine Presents Latest AI Drug Discovery Methods at Inaugural Taiwan PDA Conference

TAIPEI, TAIWAN – Media OutReach – November 7, 2018 –
Insilico Medicine, a Rockville-based company specializing in the application of
next-generation artificial intelligence for drug discovery, biomarker
development, and aging research, was invited to speak at the�first PDA
(Parenteral Drug Association) conference to be held in Taiwan, the 2018 PDA
Drug Delivery of Injectables Conference.

 

The conference, a four-day
event featuring both exhibitions and in-depth courses, is being held at Taipei’s Regent Hotel, from
November 6-9, 2018. Artur
Kadurin, InSilico Medicine’s Chief AI Officer and CEO of Insilico Taiwan,
has been invited to present a course focusing on the application of artificial intelligence (AI) for
drug discovery and other solutions. He will also participate in a panel
discussion to discuss the opportunities and challenges presented by AI.

 

The 2018 PDA Drug Delivery
of Injectables Conference is jointly organized by PDA, the Ministry of Economic
Affairs (MOEA), the Biotechnology and Pharmaceutical Industry Promotion Office
(BPIPO) and SHL Group (Scandinavian Health Limited).

 

Experts from around the
world will be attending the conference to share key information and insights on
the latest drug delivery devices, smart manufacturing, international quality
systems regulations, market trends, niche products and the application of
connected medical devices in the pharmaceutical industry. The conference is a
key component in promoting Taiwan’s pharmaceutical industry to the world while enhancing and accelerating
international cooperation between local manufacturers and the global
pharmaceutical industry.

 

Mr. Kadurin will participate in the afternoon
panel session on November 7th to discuss AI in the context of advantages for
patients, doctors, the pharmaceutical industry and insurance companies;
drivers, challenges and hurdles; business opportunities for pharma, electronics,
and the IT industry, as well as opportunities for Taiwan.

 

The panel will be jointly hosted by Dr. Herbert
Wu, President of Development Center for Biotechnology (DCB) and Markus Bauss, Managing Director of SHL Connect. In addition
to Mr. Kadurin, other panelists will include: Dr. Jai-Yen Chen, Senior Reviewer
in Division of Medical Devices, Center for Drug Evaluation; Alex Dee, Vice
President, Product Marketing, FIC; Mathias Romacker, Senior Director, Device
Strategy/Marketing, Pfizer, Inc; Kimmy Chang Chien, Sanofi Taiwan; and Thomas
Schoenknecht, PhD, Executive Director, Business Development, SHL Group.

 

With the global population and life expectancy
ever increasing, the global pharmaceutical industry continues to experience
rapid growth. Each year, total revenue reaches new highs. Likewise, research
and development into innovative new drugs and methods to treat diseases, both
old and new, continues to expand. New techniques such as AI that utilize innovative, previously impossible methods, are
receiving increasing attention.

 

With the recent development of deep learning
technology, AI has shown amazing results in a variety of fields. On November
8th, Mr. Kadurin will offer an in-depth course titled: “Use of Artificial
Intelligence for Drug Discovery.” The course will explore AI’s role in the
emerging future of interdisciplinary collaboration between medical devices and
pharmaceuticals, and illustrate the great success of AI’s applications in
biomedicine after the rise of deep learning.

 

The Parenteral Drug Association (PDA) is the
leading global facilitator of science, technology, and regulatory information.
In cooperation with the US FDA, PDA creates awareness and understanding of
important issues facing the pharmaceutical and biopharmaceutical community and
delivers education for the community, including international conferences and
related training to assist governments and pharmaceutical firms around the
world. PDA trains members in production, quality control, and quality assurance
and other related operations and management personnel, thereby helping to
enhance the relevant expertise and knowledge in the production of sterile
preparations and biological preparations.

 

This year’s PDA conference is being held in
Taiwan for the first time, with an aim towards helping upgrade Taiwan’s
pharmaceutical industry through the application of emerging technologies. The
focus of this year’s conference was on collaborative business challenges in the
successful development of pharmaceuticals, medical materials, and devices, with
a special focus on the future applications of AI in drug discovery and
development.

 

About Insilico
Medicine, Inc. / Insilico Taiwan Ltd.

Insilico Medicine is an
artificial intelligence company with R&D offices and resources in the US,
Belgium, Russia, the UK, Taiwan, and Korea, sourced through hackathons and
competitions. The company and its scientists are dedicated to extending human
productive longevity and transforming every step of the drug discovery and drug
development process through excellence in biomarker discovery, drug
development, digital medicine, and aging research.

 

Insilico pioneered the
applications of the generative adversarial networks (GANs) and reinforcement
learning for generation of novel molecular structures for diseases with a known
ligand and with no known targets. In addition to working collaborations with
large pharmaceutical companies, the company is pursuing internal drug discovery
programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease,
Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a
partnership with LifeExtension.com the company launched a range of
nutraceutical products, compounded using advanced bioinformatics and deep
learning techniques. It also provides a range of consumer-facing applications,
including Young.AI.

 

In 2017, NVIDIA selected
Insilico Medicine as one of the Top 5 AI companies for potential in social
impact. In 2018, the company was named one of the global top 100 AI companies
by CB Insights. In 2018 it received the Frost & Sullivan 2018 North
American Artificial Intelligence for Aging Research and Drug Development Award
accompanied by industry brief.

 

Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

http://www.insilico.com

 

Contact Information

Artur Kadurin, CEO of
Insilico Taiwan Ltd.

artur@insilico.com

Roger Lai, Consultant

jclai@swem.com.tw